drugset / Trial / NCT04049448
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
NaSingle-groupOpen-labelTreatment
Summary
A phase 2a open-label study to evaluate the long-term safety and efficacy of ABX464 50mg as maintenance therapy in patients with moderate to severe rheumatoid arthritis.
Timeline
- Start
- 2019-10-25
- Primary completion
- 2023-01-23
- Completion
- 2023-01-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obefazimod | Small molecule | 50 mg | Oral |